全球生物制品销售额预计将从2020年的约3250亿美元增长到2024年的4250亿美元，预计年复合增长率约为7%*。
糖尿病是一种严重的慢性疾病，其患病率在过去几十年中一直稳步增长。
2014年，全球共有4.22亿成人患有糖尿病，而在1980年，这一数字为1.08亿；这反映出超重或肥胖等相关风险因素有所增加。近期，低收入和中等收入国家糖尿病患病率的上升速度已超过高收入国家*。
这些疗法要求高度可靠性且以大批量供应，避免产线停止，减少误拒。此外，对于像卡式瓶这样的容器，与笔式注射器、自动注射器和可穿戴装置等给药系统匹配使用是至关重要的。因此，必须充分评估容器密封系统/装置的兼容性，为终端用户和患者提供可靠有效的给药方法。
*来源：2016年世界卫生组织《全球糖尿病报告》
Drug Containment Solutions
几十年来，斯蒂瓦那托集团一直为胰岛素市场领先的制药公司提供最好的玻璃内包材：如今，斯蒂瓦那托致力于糖尿病治疗，成为全球首个最大的玻璃卡式瓶制造商。
Diagnostic components
我们生产具有集成诊断功能的定制化诊断和实验室耗材、医疗点耗材以及手持器械。
Novel glass primary packaging and drug delivery devices suitable for the new generation of drugs combined with state-of-art analytical services and reliable technologies.
We have become a key partner for pharmaceutical companies specializing in anticoagulants providing glass syringes, safety systems, and state of the art technologies such as automatic vision inspection and high yield handling systems
We offer different solutions linked to sublingual and nasal drug administration. Effective, safe, and simple drug delivery guide our R&D in this field.
We provide our clients specializing in diabetes treatment with reliable and effective products, services, and technologies, from ready-to-fill glass cartridges up to user-friendly drug delivery devices.
Novel glass primary packaging and drug delivery devices suitable for the new generation of drugs combined with state-of-art analytical services and reliable technologies.
We have become a key partner for pharmaceutical companies specializing in anticoagulants providing glass syringes, safety systems, and state of the art technologies such as automatic vision inspection and high yield handling systems
We offer different solutions linked to sublingual and nasal drug administration. Effective, safe, and simple drug delivery guide our R&D in this field.
We provide our clients specializing in diabetes treatment with reliable and effective products, services, and technologies, from ready-to-fill glass cartridges up to user-friendly drug delivery devices.